University of California

Reproductive Partners Medical Group, an Ivy Fertility Clinic, Expands With New Providers And New Location

Retrieved on: 
Wednesday, February 14, 2024
Women, Baby, Maternity, Genetics, Biotechnology, Family, Other Health, Managed Care, Health, Consumer, Infertility, Research, Suite, Reproductive medicine, MD, Dartmouth College, Physician, Growth, Molecular biology, Fertility, University, University of California, Davis, Immunology, Patient, University of California, California State University, Heart, Harvard Medical School, UCLA, RPMG, Medical device

Dr. Chang and Dr. Brower are both double board certified reproductive endocrinologists and infertility specialists.

Key Points: 
  • Dr. Chang and Dr. Brower are both double board certified reproductive endocrinologists and infertility specialists.
  • “Reproductive Partners Medical Group has stayed at the forefront of our field by honoring our heritage of excellence while continually looking toward the future,” said Lab Medical Director Gayane Ambartsumyan, MD.
  • She received her medical degree from University of California, Davis, and completed her residency in Obstetrics, Gynecology, and Reproductive Medicine at Harvard Medical School.
  • “This is an exciting time to join Reproductive Partners Medical Group and Ivy Fertility,” said Dr. Brower.

ACTG Announces Launch of Clinical Trial Evaluating Drug-Drug Interaction in Shortened Tuberculosis Regimen Among People Living with HIV

Retrieved on: 
Wednesday, February 14, 2024
Infection, Bangladesh Technical Education Board, Tuberculosis, NIAID, Blood, Safety, ACTG, Trial of the century, TB, Risk, University, ART, Rifapentine, University of London, University of California, Johns Hopkins University, UM1, Pharmacokinetics, Diagnosis, Ageing, HIV, Research, University of North Carolina, Pharmaceutical industry

Previously, ACTG study A5349 demonstrated that a four-month, four-drug TB regimen that included high-dose rifapentine was as effective as the standard six-month regimen, cutting the treatment time by one third.

Key Points: 
  • Previously, ACTG study A5349 demonstrated that a four-month, four-drug TB regimen that included high-dose rifapentine was as effective as the standard six-month regimen, cutting the treatment time by one third.
  • “Understanding the relationship between these anti-TB and HIV medications is crucial, as an estimated one third of people living with HIV worldwide are at risk for developing TB,” said ACTG Chair Judith Currier, M.D., M.Sc., University of California, Los Angeles.
  • Dolutegravir is being supplied to study A5406 by ViiV Healthcare Ltd and the fixed-dose combination of dolutegravir/tenofovir disoproxil fumarate/lamivudine is being supplied by Viatris.
  • The ACTG is led by Dr. Currier and Joseph J. Eron, M.D., University of North Carolina (ACTG Vice Chair).

Abridge Announces “Abridge Inside” with Epic Integration from Haiku to Hyperdrive

Retrieved on: 
Tuesday, February 13, 2024
Health, Technology, Health Technology, Artificial Intelligence, Software, Pillar, Hospital, Spark Capital, ViVe, Multimedia, MD, Scan Group, University, HIMSS, Physician, Thought, Workshop, Bed, Emory Healthcare, UPMC, Life, Documentation, UC, Mayo Clinic, American College, Patient, University of California, Burnout, Union Square Ventures, Electronic health record, Investment, Research, Workflow, Nursing

Abridge, the leader in evidence-based generative AI for clinical documentation, today announced Abridge Inside—a new offering embedded inside standard Epic workflows.

Key Points: 
  • Abridge, the leader in evidence-based generative AI for clinical documentation, today announced Abridge Inside—a new offering embedded inside standard Epic workflows.
  • From recording patient conversations in Haiku to embedding AI-generated notes within the patient chart in Hyperdrive, clinicians will be able to harness the power of Abridge from start to finish without ever leaving Epic.
  • Both Abridge and Epic see ambient listening as a core component of a broader push to help providers improve the care experience with generative AI.
  • Abridge, led by a practicing cardiologist—Shiv Rao (CEO, co-founder)—will bring its purpose-built AI technology directly inside Epic.

RTW Charitable Foundation Announces Six Research Grant Recipients

Retrieved on: 
Monday, February 12, 2024
Biotechnology, Health, Philanthropy, Pharmaceutical, Neurology, Research, Fund Raising, Genetics, Foundation, Science, Clinical Trials, Therapy, RTW, University College London, Grant (money), Metabolism, Toxicity, Doctor of Philosophy, IRF2BPL, Nationwide, University, Gene, Nonprofit organization, Growth, Hospital, Life, Weakness, Translation, University of California, Patient, NIHR, Child, AAV, Kidney transplantation, Kidney failure, Pharmaceutical industry

RTW Charitable Foundation (“RTWCF”) announced today that it has awarded $900,000 in research grants to support six research studies.

Key Points: 
  • RTW Charitable Foundation (“RTWCF”) announced today that it has awarded $900,000 in research grants to support six research studies.
  • “Optimizing AAV-SPL gene therapy for sphingosine phosphate lyase insufficiency syndrome” (Julie Saba, University of California, San Francisco, San Francisco, CA).
  • “RTW Charitable Foundation is proud to provide financial and scientific support to these six incredible researchers and their respective studies.
  • In addition to delivering financial resources, RTWCF also provides grant recipients with hands-on scientific support, helping them improve or further develop their research and research tools and identify new therapeutic targets.

More than 78 ‘friends’ of the Supreme Court offer advice on the 14th Amendment and Trump’s eligibility

Retrieved on: 
Tuesday, February 6, 2024
Section 3, Students for Fair Admissions, Student, Knowledge, Reconstruction, School, Congress, Supreme court, Republican, History, Constitution, University, Supreme, Constitutional right, First, Justice, Colorado Supreme Court, Harvard University, Capitol police, Justice minister, White, University of California, Yale Law School, Democracy, Violence, Unexpected, National Association

The justices will hear oral arguments in that case, Trump v. Anderson, on Feb. 8.

Key Points: 
  • The justices will hear oral arguments in that case, Trump v. Anderson, on Feb. 8.
  • 2024.
  • When the Colorado Supreme Court ruled that Trump could not appear on that state’s ballot, Trump appealed the decision to the U.S. Supreme Court.
  • While the Supreme Court will ultimately determine Trump’s fate, the numerous parties who have chimed in aim to add context and additional arguments for the justices to consider.

78 amicus briefs

  • They describe this as an effort to “prevent the lawful inauguration of duly elected Abraham Lincoln.” Others file amicus briefs to advance or further an argument.
  • All share a common thread: Amicus briefs are filed to help the court shape the ruling in the case.
  • In Trump v. Anderson, the amicus filers who support Trump filed 34 briefs.
  • The total of 78 amicus briefs filed is lower than other recent and controversial cases before the Supreme Court.
  • While normally there is a period of months to file amicus briefs in cases, the court’s expedited timeline directed amicus filers that they had less than four weeks to file their briefs.

Constitutional or unconstitutional?

  • Trump incited, and therefore engaged in, an armed insurrection against the Constitution’s express and foundational mandates that require the peaceful transfer of executive power to a newly elected President.” Constitutional law scholars such as Berkeley’s Erwin Chemerinsky and Yale’s Bruce Ackerman argue in their filing that Trump’s rhetoric is not protected by the First Amendment.
  • Thus, they write, the First Amendment should not affect how the court interprets and applies Section 3.
  • And the National Association for the Advancement of Colored People argues that the court should give consideration to the 14th Amendment’s commitment to equal protection and multiracial democracy because the drafters of the amendment had a “practical concern about how insurrectionists would respect the rights of those whom they did not believe were entitled to rights.”

Unexpected friends

  • Although legal scholars and politicians frequently file amicus briefs in cases, this case also generated significant interest from nontraditional amici.
  • An unspecified number of Capitol Police officers who fought against the rioters on Jan. 6, 2021, to protect senators and representatives argue that the First Amendment should not apply because Trump’s speech was “integral to unlawful activity”.
  • Voters in New Hampshire argue that all Americans have a constitutional right to “a ballot free of such an insurrectionist” as Trump.

‘Great peril’ for the nation

  • Trump’s supporters argue that Section 3 does not apply to the office of the president.
  • Even if it did, they assert, Trump’s speech should be protected by the First Amendment.
  • Anderson’s supporters who seek Trump’s disqualification argue that Section 3 does apply to the president.
  • And both sides argue that the Supreme Court must decide the issue now because any delay will “place the Nation in great peril”.


Wayne Unger does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024

Retrieved on: 
Monday, February 5, 2024
SAN, UCSF, University of California, Pancreatic cancer, CTGF, Pamrevlumab, Virginia Mason Medical Center, MMM, ADC, University, KOL, Pancreatic Cancer Action Network, Pharmaceutical industry

SAN FRANCISCO, Feb. 05, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced it will host Part I of a virtual KOL investor event series on Tuesday, February 13, 2024 at 10:30 AM ET.

Key Points: 
  • SAN FRANCISCO, Feb. 05, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced it will host Part I of a virtual KOL investor event series on Tuesday, February 13, 2024 at 10:30 AM ET.
  • To register, click here .
  • The second event in the series, to be scheduled at a later date, will include a review of the development program for FG-3246; a Phase 2 ready CD46 targeting antibody-drug conjugate (ADC) for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
  • This series is intended for investor audiences only.

Ibogaine By David Dardashti Shares Insight On New Study By Stanford University

Retrieved on: 
Thursday, February 1, 2024
The Journal of Neuroscience, GDNF, University of California, Memory, Growth, Inflammation, Immunity, Cell, Immune system, Research, Psychological trauma, Patient, Serotonin, Mevalonate pathway, Stanford University, Harvard University, Brain damage, Depression, Medical News Today, Mental health, Trauma, Blood, Nervous system, Communication, Brain, National library, Insulin, Journal, University, Health, Cognition, Medicine, Regulation, Vaccine

The study, which involved soldiers who had experienced both physical and psychological trauma, offers insight towards the potential therapeutic benefits of ibogaine.

Key Points: 
  • The study, which involved soldiers who had experienced both physical and psychological trauma, offers insight towards the potential therapeutic benefits of ibogaine.
  • The University of California has asserted that ibogaine has the ability to increase serotonin levels, which may contribute to the recovery of damaged brain cells.
  • Medicalnewstoday, a leading source of medical news and information, has also reported on the potential of ibogaine in promoting cell recovery.
  • Ibogaine By David Dardashti is proud to be at the forefront of this research and looks forward to further advancements in the field.

Hico Management Launches 'Hico-Bow Joint Fund', Attracting External LPs. Accelerating AI Investments in the Tech Innovation Hub of Silicon Valley

Retrieved on: 
Thursday, February 1, 2024
Partnership, Multimedia, SK Group, Sacramento Kings, University of California, AI, MOU, Health, Digital transformation, CVC, DT, Investment, LP record, UC, University, Hospital, Cryptocurrency

This was done through a joint fund formed in partnership with Bow Capital, a globally influential venture investment firm.

Key Points: 
  • This was done through a joint fund formed in partnership with Bow Capital, a globally influential venture investment firm.
  • SK Networks (CEO : Hojeong Lee) announced on February 1 that Hico Management and Bow Capital Management formed a joint fund.
  • This joint fund was formed by Hico Management in collaboration with Bow Capital Management.
  • Hico Management is an investment management subsidiary of Hico Capital that leads SK Networks' operation in the U.S.

University of Nebraska, Lincoln Takes Top Honors at 22nd Annual Deloitte FanTAXtic National Case Study Competition

Retrieved on: 
Tuesday, January 30, 2024
Well, Student, Learning, University at Albany, SUNY, University of Houston, University, Champaign, Illinois, San Diego State University, School, University of Massachusetts, Faculty, Florida International University, University of Cincinnati, University of Utah, University of Mississippi, Depreciation, Creativity, University of California, Jackson State University, University of Tennessee, University of Nebraska–Lincoln, Lincoln, University of Florida, University of Illinois Urbana-Champaign, University of Southern California

NEW YORK, Jan. 30, 2024 /PRNewswire/ -- A team of students from University of Nebraska, Lincoln, claimed victory at the Deloitte FanTAXtic national case study competition by presenting the best analysis on a complex, issues-driven business tax case. This year's case challenged teams to provide advice on how to structure a new business entity and help determine whether they should operate the venture as an S corporation or a C corporation. Teams were also asked to share advice on tax issues like how to calculate depreciation, when to recognize income, and how to calculate a specific business income deduction. The national finals were held Jan. 19-21 at Deloitte University, Deloitte's landmark campus for learning and leadership development in Westlake, Texas.

Key Points: 
  • NEW YORK, Jan. 30, 2024 /PRNewswire/ -- A team of students from University of Nebraska, Lincoln, claimed victory at the Deloitte FanTAXtic national case study competition by presenting the best analysis on a complex, issues-driven business tax case.
  • The national finals were held Jan. 19-21 at Deloitte University, Deloitte's landmark campus for learning and leadership development in Westlake, Texas.
  • The other teams that participated were: Florida International University; San Diego State University; University at Albany; University of California, Los Angeles; University of Cincinnati; University of Florida; University of Houston; University of Illinois, Urbana – Champaign; University of Massachusetts; University of Mississippi; University of Southern California; University of Tennessee; and University of Utah.
  • Each of the 16 teams participating in the national competition won the Deloitte FanTAXtic contest in their respective U.S. regions.

Elicio Therapeutics to Present ELI-002 7P (AMPLIFY-7P) Trial in Progress Poster on Phase 1/2 Study of Lymph Node-Targeted Vaccine at ASCO GI Symposium

Retrieved on: 
Wednesday, January 17, 2024
Tumor microenvironment, Development, Death, Pancreatic cancer, Patient, Therapy, Cancer, Neoplasm, DNA, Pancreas, Standard of care, Survival, AMP, Poster, University, Lymphocyte, Risk, HLA, Safety, UCLA, Lymph, CA19-9, Immunization, University of California, PDAC, Research and development, Observation, Biopsy, Colorectal cancer, Nature Medicine, RAS, Pharmaceutical industry

The poster describes AMPLIFY-7P, a Phase 1 and randomized Phase 2 study of ELI-002 7P, an investigational therapeutic cancer vaccine, administered as an adjuvant monotherapy treatment for patients with KRAS-mutated pancreatic ductal adenocarcinoma (“PDAC”).

Key Points: 
  • The poster describes AMPLIFY-7P, a Phase 1 and randomized Phase 2 study of ELI-002 7P, an investigational therapeutic cancer vaccine, administered as an adjuvant monotherapy treatment for patients with KRAS-mutated pancreatic ductal adenocarcinoma (“PDAC”).
  • “We are progressing our AMP-powered, lymph node-targeted cancer vaccine, ELI-002 7P, as a monotherapy in an adjuvant setting for patients with pancreatic cancer, and recently dosed the first patient in the randomized Phase 2 cohort.
  • AMPLIFY-7P is a Phase 1 and Phase 2 study of ELI-002 7P in patients with RAS mutated pancreatic and colorectal tumors after locoregional treatment.
  • A Phase 2 interim analysis is planned using group sequential design for control of overall alpha 0.10.